#tenofovir alafenamide

Previous studies of the association between tenofovir and COVID-19 outcomes in people with HIV have yielded mixed results.

People living with both viruses remain at risk for hepatocellular carcinoma despite antiviral therapy.

Two different studies found that Vemlidy was safe and effective for pregnant women and their infants.

Researchers have called for revised treatment guidelines to address the higher risk of fracture in the HIV population.

A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.

Swiss researchers analyzed shifts in kidney function among those switching from the old form of the HIV medication to the new one.

Gilead Sciences has released multiple combo tablets that contain the updated tenofovir, which is linked to improved bone and kidney makers.

The once-daily regimen includes the integrase inhibitor bictegravir plus the contents of Descovy (emtricitabine/tenofovir alafenamide).

Largest-ever analysis of bone loss in the HIV population found that treating hep C, taking vitamin D and exercising might be preventive.

If you have a relatively healthy liver and cleared hepatitis B “e” antigen, is it possible to stop taking hepatitis B antivirals?

A 96-week study also found that switching from Viread to Vemlidy led to improvements in liver enzyme levels.

Learn 10 things you should know about hepatitis B and do in 2017

An updated version of Viread, called TAF, combats hepatitis B as effectively as the older drug and is safer for bone and kidney health.

Since curing HCV, Gilead has more than doubled its annual drug sales, leaving the company with $8.61 billion for further investments.